SARM1 激活、底物识别和小分子抑制的结构基础。
Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.
机构信息
Institute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
出版信息
Mol Cell. 2022 May 5;82(9):1643-1659.e10. doi: 10.1016/j.molcel.2022.03.007. Epub 2022 Mar 24.
The NADase SARM1 (sterile alpha and TIR motif containing 1) is a key executioner of axon degeneration and a therapeutic target for several neurodegenerative conditions. We show that a potent SARM1 inhibitor undergoes base exchange with the nicotinamide moiety of nicotinamide adenine dinucleotide (NAD) to produce the bona fide inhibitor 1AD. We report structures of SARM1 in complex with 1AD, NAD mimetics and the allosteric activator nicotinamide mononucleotide (NMN). NMN binding triggers reorientation of the armadillo repeat (ARM) domains, which disrupts ARM:TIR interactions and leads to formation of a two-stranded TIR domain assembly. The active site spans two molecules in these assemblies, explaining the requirement of TIR domain self-association for NADase activity and axon degeneration. Our results reveal the mechanisms of SARM1 activation and substrate binding, providing rational avenues for the design of new therapeutics targeting SARM1.
SARM1(含无菌α和 TIR 基序 1 的烟酰胺腺嘌呤二核苷酸酶)是轴突退化的关键执行者,也是几种神经退行性疾病的治疗靶点。我们表明,一种有效的 SARM1 抑制剂与烟酰胺腺嘌呤二核苷酸(NAD)的烟酰胺部分进行碱基交换,生成真正的抑制剂 1AD。我们报告了 SARM1 与 1AD、NAD 类似物和别构激活剂烟酰胺单核苷酸(NMN)复合物的结构。NMN 结合触发了类角质蛋白重复(ARM)结构域的重新定向,这破坏了 ARM:TIR 相互作用,并导致形成双链 TIR 结构域组装。在这些组装体中,活性位点跨越两个分子,这解释了 TIR 结构域自身缔合对于 NAD 酶活性和轴突退化的要求。我们的结果揭示了 SARM1 激活和底物结合的机制,为靶向 SARM1 的新型治疗药物的设计提供了合理的途径。
相似文献
Proc Natl Acad Sci U S A. 2022-8-30
Proc Natl Acad Sci U S A. 2021-1-26
Proc Natl Acad Sci U S A. 2016-10-11
引用本文的文献
Nat Chem Biol. 2025-8-22
bioRxiv. 2025-5-15
Front Immunol. 2025-5-13
Nature. 2025-4-30
bioRxiv. 2025-2-21
本文引用的文献
Proc Natl Acad Sci U S A. 2021-1-26